[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)]
[Article in German]
- PMID:5344299
Item in Clipboard
[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)]
[Article in German]
W Birkmayer. Wien Klin Wochenschr..
Display options
Format
Display options
Format
No abstract available
Similar articles
- [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].Kaufmann W, Butz P, Wiesendanger M.Kaufmann W, et al.Dtsch Z Nervenheilkd. 1970;197(1):85-100.Dtsch Z Nervenheilkd. 1970.PMID:5522871German.No abstract available.
- [Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].Kaufmann W, Butz P, Wiesendanger M.Kaufmann W, et al.Dtsch Z Nervenheilkd. 1969 Dec 29;197(1):85-100.Dtsch Z Nervenheilkd. 1969.PMID:5364658German.No abstract available.
- [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].Siegfried J, Klaiber R, Perret E, Ziegler WH.Siegfried J, et al.Dtsch Med Wochenschr. 1969 Dec 26;94(52):2678-81. doi: 10.1055/s-0028-1110503.Dtsch Med Wochenschr. 1969.PMID:4903342Clinical Trial.German.No abstract available.
- [Review of current pharmacotherapy of Parkinsonism. Comprehensive review].Benesová O.Benesová O.Cesk Neurol. 1973 May;36(3):196-205.Cesk Neurol. 1973.PMID:4574253Review.Czech.No abstract available.
- L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.Goodwin FK, Murphy DL, Brodie HK, Bunney WE Jr.Goodwin FK, et al.Biol Psychiatry. 1970 Oct;2(4):341-66.Biol Psychiatry. 1970.PMID:4920729Review.No abstract available.
Cited by
- Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.Marsden CD, Barry PE, Parkes JD, Zilkha KJ.Marsden CD, et al.J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10-4. doi: 10.1136/jnnp.36.1.10.J Neurol Neurosurg Psychiatry. 1973.PMID:4691682Free PMC article.
- Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.Sethi KD, Hauser RA, Isaacson SH, McClain T.Sethi KD, et al.Cases J. 2009 Jul 30;2:7134. doi: 10.4076/1757-1626-2-7134.Cases J. 2009.PMID:19829918Free PMC article.
- Iron, a new aid in the treatment of Parkinson patients.Birkmayer W, Birkmayer JG.Birkmayer W, et al.J Neural Transm. 1986;67(3-4):287-92. doi: 10.1007/BF01243354.J Neural Transm. 1986.PMID:3806082
- Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ.Katzenschlager R, et al.J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7. doi: 10.1136/jnnp.2003.028761.J Neurol Neurosurg Psychiatry. 2004.PMID:15548480Free PMC article.Clinical Trial.
- L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.Riederer P, Horowski R.Riederer P, et al.J Neural Transm (Vienna). 2023 Nov;130(11):1323-1335. doi: 10.1007/s00702-023-02692-9. Epub 2023 Oct 5.J Neural Transm (Vienna). 2023.PMID:37796288Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Research Materials